11.
nov. 2021
The 8th National Microbiota Conference
We are very happy to welcome you to the 8th National Microbiota Conference on microbiota in health and disease.
The conference will be held at Radisson Blu Scandinavia in Oslo city center from 10:00 to 16:30. Lunch and refreshments are included.
Please click below to register within November 1, 2021

Agenda

Keynote Lecturer
Marcus Claesson

After a BSc in Chemical Engineering and MSc in Bioinformatics at Chalmers University of Technology in Gothenburg, Marcus completed his PhD at University College Cork (UCC) sequencing and comparing commensal Lactobacillus species. This was followed by postdoctoral fellowships mining probiotic bacteria and analysing the microbiomes of older people as part of the ELDERMET project.
Marcus is now a PI at APC Microbiome Ireland, UCC, where his main research interests in the role of microbiota in inflammatory bowel disease, and methods development for various 'omics' technologies. He is also coordinating the MSc programme in Bioinformatics and Computational Biology, and lectures on the subject to MSc, Microbiology and Genetics students.
In 2020, Marcus co-founded SeqBiome Ltd, a spin-out company providing high-quality microbiome analysis for industry and academia.

Keynote Lecturer
Daniel Globisch

Associate Professor Daniel Globisch started his independent research group in 2015 at Uppsala University as a Science For Life Laboratory Fellow. He has been appointed as Associate Professor in April 2017 and received tenure in December 2020.
His PhD degree was awarded from the Ludwig-Maximilians-University Munich (Germany) in 2011, where he quantified natural RNA/DNA modifications using mass spectrometric techniques. For his postdoctoral studies, he joined The Scripps Research Institute, La Jolla, CA (USA) working on bacterial quorum sensing and metabolomics analysis. During his 4,5 year stay, Dr. Globisch discovered the urinary biomarker N-acetyltyramine-O-glucuronide (NATOG) using a metabolomics mining approach for the neglected tropical disease onchocerciasis, for which he developed an antibody-based urine dipstick test.
In his laboratory, Dr. Globisch’s research focus lies on the development of new Chemical Biology tools to enhance the scope of metabolomics research. His interdisciplinary research projects integrate global metabolomics, organic chemistry as well as Chemical Biology and are focused on elucidating the metabolic interaction between microbiota and their human host. He explores the potential of microbiota metabolism as a new strategy for the discovery of unknown biomarkers for pancreatic and colorectal cancer as well as unknown bioactive metabolites produced by the gut microbes.